Skip to main content
. 2024 Feb 28;5(4):100657. doi: 10.1016/j.jtocrr.2024.100657

Figure 2.

Figure 2

(A) Timeline of the patient’s clinical course. Temporal changes in chest X-ray images after (B) the initiation and (C) the discontinuation of lenvatinib. †, passed away. AMR, amrubicin; CBDCA, carboplatin; HEP, liver metastases; RECIST, Response Evaluation Criteria in Solid Tumors; PD, progressive disease; PLE, pleural metastases; PR, partial response; PTX, paclitaxel; RT, radiation therapy; SVC, superior vena cava.